2m 2m 2m 2m 2m 2m 2m
Halozyme Therape (HALO)
NASDAQ
$82.43-$0.12 (-0.14%)
Price as of Aug 03, 2026 6:05 AM EDT- $9.8BMarket Cap
- 39.85%1-Year Change
- BiotechnologyIndustry
Halozyme Therape (HALO)
$82.43-$0.12 (-0.14%)
HALO | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $82.54 | ||
Change | -$0.76 (-0.91%) | ||
Open | $83.19 | ||
High | $83.27 | ||
Low | $81.50 | ||
Previous Close | $83.30 | ||
Volume | 1,558,901 | ||
30-Day Average Volume | 1,774,163 | ||
1-Week Change | 0.74% | ||
1-Month Change | 5.46% | ||
1-Year Change | 39.85% | ||
3-Year Change | 92.13% | ||
5-Year Change | 99.71% | ||
Fundamentals | |||
Shares Outstanding | 118.6M | ||
Total Assets | $2.7B | ||
Market Cap | $9.8B | ||
Enterprise Value | $11.6B | ||
Period: QTR TTM FY | |||
Revenue | $240.7M | ||
Net Income | $150.0M | ||
Free Cash Flow | $176.3M | ||
EBIT | $180.7M | ||
EBITDA | $210.2M | ||
Net Working Capital | $639.8M | ||
EPS | $1.22 | ||
Enterprise Value/EBITDA | 55 | ||
Enterprise Value/Revenue | 48 | ||
P/B | 45 | ||
P/E | 68 | ||
PEG | 0 | ||
Price/Free Cash Flow | 56 | ||
Price/Operating Cash Flow | 54 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue